Illumina, Inc.

5.02(d) On June 1, 2023, the Board of Directors (the “Board”) of Illumina, Inc. (the “Company”) increased the size of the Board from nine to eleven members and elected Stephen P. MacMillan and Scott B. Ullem to serve on the Board beginning June 1, 2023. Mr. MacMillan will serve as non-executive Chair of the Board. Mr. Ullem will serve on the Audit Committee of the Board. Messrs. MacMillan and Ullem will each stand for election at the Company’s 2024 annual meeting of stockholders to serve for a one-year term commencing with such meeting. There is no arrangement or understanding between either Mr. MacMillan or Mr. Ullem and any other person pursuant to which he was selected as a director. In addition, neither Mr. MacMillan nor Mr. Ullem is a party to any transaction with the Company reportable under Item 404(a) of Regulation S-K under the Securities Act of 1933. Messrs. MacMillan and Mr.

The information included in the description of the fifth proposal under

(e) On February 1, 2023, the Board of Directors (the “Board”) of Illumina, Inc., a Delaware corporation (the “Company”), approved, an amendment and restatement of its 2015 Stock and Incentive Plan (the “Plan”) to increase the share reserve under the Plan by 8,000,000 shares, extend the term until January 31, 2033, eliminate specified requirements and limitations that applied to the grant of awards that were previously intended to constitute “qualified performance-based compensation” under Section 162(m) of the Internal Revenue Code in light of certain changes in tax law under the Tax Cuts and Jobs Act, permit the Plan administrator to grant dividend equivalent rights, specify the change in control treatment that will apply to outstanding awards in connection with a change in control of the Company and make other immaterial and ministerial changes.

(c) and (e) On February 1, 2023, Illumina, Inc. (the “Company”) announced that Joydeep Goswami, Chief Strategy and Corporate Development Officer & Interim Chief Financial Officer of the Company, has been appointed as Chief Financial Officer of the Company, effective January 31, 2023 (the “Appointment Date”). Mr. Goswami will continue to serve as principal financial officer for purposes of the Company’s filings with the Securities and Exchange Commission. Mr. Goswami, age 51, has served as Chief Strategy and Corporate Development Officer & Interim Chief Financial Officer of the Company since June 2022. He has served as Chief Strategy and Corporate Development Officer of the Company since 2021 and served as Senior Vice President, Corporate Development & Strategic Planning from 2019 to 2021.

On September 29, 2022 Illumina, Inc. (the “Company”) appointed Scott Ericksen as Vice President and Chief Accounting Officer, effective as of October 16, 2022. In this role, Mr. Ericksen will serve as principal accounting officer for purposes of the Company’s filings with the Securities and Exchange Commission. Mr. Ericksen, age 50, has served in roles of increasing responsibility with the Company since November 2013, including in his most recent role as International Controller since September 2021 and, prior to that, as EMEA Controller from August 2019 through September 2021, Senior Director, Technical Accounting from September 2018 through August 2019 and Director, Technical Accounting from June 2016 through August 2019. Prior to Illumina, Mr. Ericksen served as Vice President, Director of Corporate Accounting at Science Applications International Corporation, Inc.

On September 14, 2022, Jose Torres, Vice President and Chief Accounting Officer, notified Illumina, Inc. (the “Company”) that he will be leaving the Company effective as of October 14, 2022. This departure is not the result of any disagreement on matters relating to the Company’s operations or its financial reporting, policies, or practices.

On June 8, 2022, Sam Samad, Chief Financial Officer, notified Illumina, Inc. (the “Company”) that he will be leaving the Company effective as of July 8, 2022. This departure is not the result of any disagreement on matters relating to the Company’s operations or its financial reporting, policies, or practices.

Effective April 19, 2021, Illumina, Inc. (the “Company”) appointed Jose Torres, Vice President and Chief Accounting Officer, as principal accounting officer for purposes of the Company’s filings with the Securities and Exchange Commission. Mr. Torres, age 46, most recently served as Chief Financial Officer of the University of St. Augustine for Health Sciences from April 2019 to April 2021. From January 2016 to March 2019, Mr. Torres served as Senior Vice President and Chief Accounting Officer of Maxar Technologies, a space technology company. Prior to Maxar Technologies, he served as Vice President, Accounting, Financial Reporting & Financial Systems at the ADT Corporation, a leader in electronic security, fire protection and other related alarm monitoring services, from February 2012 to December 2015. Mr.

Illumina, Inc. (the “Company”) today announced that Jay Flatley has decided to step down from the Board of Directors, and John W. Thompson will be appointed as the Company’s new Chair of the Board. These changes will be effective as of the Company’s Annual Shareholder Meeting on May 26, 2021. A copy of the press release making this announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

On August 19, 2020, Karen McGinnis, Vice President & Chief Accounting Officer, notified Illumina, Inc. that she would be retiring effective as of April 2, 2021.

On May 6, 2020, Omead Ostadan, Senior Vice President & Chief Product and Marketing Officer, informed Illumina, Inc. that he would be leaving the company effective as of June 12, 2020.

5.02(d) On February 4, 2020 , the Board of Directors (the “Board”) of Illumina, Inc. (the “Company”) increased the size of the Board from nine to ten members and elected Scott Gottlieb, to serve on the Board beginning February 4, 2020. Dr. Gottlieb will stand for election at the Company’s 2020 annual meeting of stockholders to serve for a one-year term commencing with such meeting. There is no arrangement or understanding between Dr. Gottlieb and any other person pursuant to which he was selected as a director. In addition, Dr. Gottlieb is not a party to any transaction with the Company reportable under Item 404(a) of Regulation S-K under the Securities Act of 1933. Dr. Gottlieb will participate in the non-employee director compensation programs described under “Director Compensation” in the Company’s proxy statement filed on April 16, 2019.

As previously disclosed in a Form 8-K filed on August 29, 2019, Garret Hampton, Senior Vice President, Clinical Genomics, informed Illumina, Inc. (the “Company”) that he would be leaving the company effective as of January 10, 2020. In connection with his departure, Dr. Hampton and the Company entered into a Separation Agreement dated as of November 25, 2019, pursuant to which Dr. Hampton will receive payments equal to (i) one year of his annual base salary ($560,000) and (ii) group health insurance premiums under COBRA for a period of 12 months. He will also be eligible to receive a performance-based cash payment under the Company’s 2019 variable compensation plan in an amount of up to $504,000. Dr. Hampton may also access certain professional outplacement services and executive physical benefits for a period of 12 months.

On August 27, 2019, Garret Hampton, Senior Vice President, Clinical Genomics, informed Illumina, Inc. that he would be leaving the company effective as of January 10, 2020, in connection with an organizational restructuring.

5.02(d) On February 5, 2019, the Board of Directors (the “Board”) of Illumina, Inc. (the “Company”) increased the size of the Board from nine to ten members and elected Susan E. Siegel, to serve on the Board beginning February 5, 2019. Ms. Siegel has been assigned to serve in the class of directors standing for election at the Company’s 2019 annual meeting of stockholders , and , consistent with the Company’s Corporate Governance Guidelines, Ms. Siegel will stand for election by the Company’s stockholders at the Company’s 2019 annual meeting of stockholders to serve for a three-year term commencing with such meeting. There is no arrangement or understanding between Ms. Siegel and any other person pursuant to which she was selected as a director. In addition, Ms.

On October 31, 2018, Marc Stapley, Executive Vice President, Strategy & Corporate Development, notified Illumina, Inc. that he would be leaving the company effective as of January 1, 2019.

Effective November 14, 2017, Illumina, Inc. (the “Company”) appointed Karen McGinnis, Vice President and Chief Accounting Officer, as principal accounting officer for purposes of the Company’s filings with the Securities and Exchange Commission. Ms. McGinnis, age 51, most recently served as President, Chief Executive Officer and a director of Mad Catz Interactive, Inc. Prior to her appointment as President and Chief Executive Officer in February 2016, Ms. McGinnis served as Mad Catz’s Chief Financial Officer since June 2013, when she joined Mad Catz. Prior to joining Mad Catz, Ms. McGinnis served as Chief Accounting Officer of Cymer, Inc. from November 2009 through May 2013. Prior to joining Cymer, Ms. McGinnis was Chief Accounting Officer for Insight Enterprises, Inc., from September 2006 until March 2009, and its Senior Vice President of Finance from 2001 through September 2006. Ms.

5.02(d) On November 2, 2017, the Board of Directors (the “Board”) of Illumina, Inc. (the “Company”) increased the size of the Board from nine to ten members and elected Gary S. Guthart, Ph.D., to serve on the Board beginning December 1, 2017. Dr. Guthart has been assigned to serve in the class of directors standing for election at the Company’s 2018 annual meeting of stockholders, which currently includes Blaine Bowman, Jay Flatley, and John Thompson, and , consistent with the Company’s Corporate Governance Guidelines, Dr. Guthart will stand for election by the Company’s stockholders at the Company’s 2018 annual meeting of stockholders to serve for a three-year term commencing with such meeting. There is no arrangement or understanding between Dr. Guthart and any other person pursuant to which he was selected as a director. In addition, Dr.

5.02(d) On February 18, 2017, the Board of Directors (the “Board”) of Illumina, Inc. (the “Company”) increased the size of the Board from ten to 11 members and elected John Thompson to serve on the Board beginning May 3, 2017. Mr. Thompson has been assigned to serve in the class of directors standing for election at the Company’s 2018 annual meeting of stockholders, which currently includes Blaine Bowman, Karin Eastham, and Jay Flatley, and consistent with the Company’s Corporate Governance Guidelines, Mr. Thompson will stand for election by the Company’s stockholders at the Company’s 2018 annual meeting of stockholders to serve for a three-year term commencing with such meeting. There is no arrangement or understanding between Mr. Thompson and any other person pursuant to which he was selected as a director. In addition, Mr.

5.02(d) Effective as of January 26, 2017, the Board of Directors (the “Board”) of Illumina, Inc. (the “Company”) increased the size of the Board from nine to ten members and elected Caroline Dorsa to serve on the Board. Ms. Dorsa has been assigned to serve in the class of directors standing for election at the Company’s 2017 annual meeting of stockholders, which currently includes Daniel Bradbury, Robert Epstein, Roy Whitfield and Philip Schiller, and, consistent with the Company’s Corporate Governance Guidelines, Ms. Dorsa will stand for election by the Company’s stockholders at the Company’s 2017 annual meeting of stockholders to serve for a three-year term commencing with such meeting. She has been appointed to serve as a member of the Audit Committee of the Board. There is no arrangement or understanding between Ms.

On December 7, 2016, Illumina, Inc. (the "Company") announced the appointment of Sam A. Samad as Senior Vice President and Chief Financial Officer of the Company. Mr. Samad will assume the position of Chief Financial Officer from Marc Stapley, who has been the Company’s Chief Financial Officer since 2012. Mr. Stapley will continue in his role with the Company as Executive Vice President and Chief Administrative Officer. Mr. Samad, 46, most recently served as Senior Vice President and Corporate Treasurer at Cardinal Health from 2012 to 2016 where, in addition to treasury, he also had leadership responsibility for Cardinal Health’s China business. From 2009 to 2012 he served as Senior Vice President and CFO of Cardinal Health’s Pharmaceutical Segment, and from 2007 to 2009 he served as Vice President, Finance of Cardinal Health’s Supply Chain Services.

On November 27, 2016, Tristan Orpin, Executive Vice President, Clinical Genomics, notified Illumina, Inc. that he would be leaving the company in January 2017. Illumina has identified and agreed to employment terms with a successor to Mr. Orpin, who will join the company in January 2017.

On October 27, 2016, Christian O. Henry, Executive Vice President and Chief Commercial Officer, notified Illumina, Inc. that he would be leaving the company at the end of January 2017.

5.02(d) Effective as of July 27, 2016, the Board of Directors (the “Board”) of Illumina, Inc. (the “Company”) increased the size of the Board from eight to nine members and elected Philip W. Schiller to serve on the Board. Mr. Schiller has been assigned to serve in the class of directors standing for election at the Company’s 2017 annual meeting of stockholders, which currently includes Daniel Bradbury, Robert Epstein, and Roy Whitfield, and, consistent with the Company’s Corporate Governance Guidelines, Mr. Schiller will stand for election by the Company’s stockholders at the Company’s 2017 annual meeting of stockholders to serve for a three-year term commencing with such meeting. There is no arrangement or understanding between Mr. Schiller and any other person pursuant to which he was selected as a director. In addition, Mr.

Director or officer change (Item 5.02). Open the filing for details.

Director or officer change (Item 5.02). Open the filing for details.

Director or officer change (Item 5.02). Open the filing for details.

Director or officer change (Item 5.02). Open the filing for details.